Full Press Release Details
Sensei Biotherapeutics Presents Preclinical Data at the
37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies -
- Characterization of endogenous expression patterns, and identification of novel T-cell receptors,
of VSIG4 enables advancement of SNS-102 program -
BOSTON, MA November 10,
2022 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented preclinical data for
SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei s discovery-stage SNS-102
program, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
presented at SITC add to the growing body of evidence that our TMAb platform is a potentially powerful approach for unlocking previously undruggable immune targets. With the advancement of SNS-101, we have a highly pH-selective antibody to VISTA, which is designed to be conditionally active within the tumor microenvironment, said Robert Pierce, M.D., Chief
R&D Officer at Sensei. We have also made exciting progress in our SNS-102 program, with the functional characterization and identification of novel T-cell
receptors that may play a role in VSIG4-mediated immunosuppression. We look forward to advancing both programs with an upcoming IND filing for SNS-101 and identification of a lead anti-VSIG4 antibody in
Presentation Highlights:
presentation titled, SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8
Summary: Sensei has developed SNS-101, a
conditionally active, human monoclonal IgG1 antibody specific for the protonated, active form of VISTA, which in preclinical studies has demonstrated the ability to disrupt the immunosuppressive VISTA:PSGL-1
interaction, avoid target-mediated drug disposition (TMDD) and mitigate potential cytokine release syndrome (CRS).
Poster presentation titled, Functional characterization of the inhibitory activity and
identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4
Summary: Sensei characterized endogenous expression patterns of VSIG4 in polarized macrophage populations and showed a robust VSIG4-mediated
suppression of primary human T-cells. Additionally, a ligand receptor capture-trifunctional chemoproteomic (LRC-TriCEPS)-based proteomics strategy identified receptors
on primary human T-cells that interact with recombinant VSIG4 protein.
A copy of the presentation materials will be added to the
Events & Presentations section of the Company s Investor Relations website at www.senseibio.com.
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints
and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei s lead investigational candidate is SNS-101, a conditionally active antibody
designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain
Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as believe , designed to, expect , may , plan , potential ,
will , and similar expressions, and are based on Sensei s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei s product candidates and platforms; the
potential safety profile of Sensei s product candidates; the potential benefits of Sensei s product candidates; the timing of selection of lead product candidates; and the timing of an IND submission to the FDA. These statements involve
risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of
therapeutic product candidates, such as the risk that any one or more of Sensei s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei s product
candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies, including the preclinical studies described in this press release, will not be replicated or will not continue
in ongoing or future studies or clinical trials involving Sensei s product candidates; the risk that Sensei s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that
we anticipate; risks associated with Sensei s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses,
capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei s Annual Report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) on November 8, 2022 and Sensei s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the
date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Senior Director, Investor Relations
Sensei Biotherapeutics
Ten Bridge Communications